Monopar Therapeutics Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Monopar Therapeutics Inc. (MNPR) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 823.13 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- Monopar Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 842.97K shares, a 9.53% increase year-over-year.
- Monopar Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 715.32K shares, a 50.04% increase year-over-year.
- Monopar Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 754.94K shares, a 53.90% increase year-over-year.
- Monopar Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 769.61K shares, a 54.81% increase year-over-year.
- Monopar Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 792.19K shares, a 68.68% increase from fiscal 2024.
- Monopar Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 469.65K shares, a 7.08% decline from fiscal 2023.
- Monopar Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 505.42K shares, a 73.62% decline from fiscal 2022.
- Monopar Therapeutics Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 1.92M shares, a 15.71% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 823.13K shares 10-Q · filed 2026-08-12 | |||||||
| 2026-03-31 | 842.97K shares 10-Q · filed 2026-05-14 | |||||||
| 2025-12-31 | 792.19K shares 10-K · filed 2026-03-27 | |||||||
| 2025-09-30 | 715.32K shares 10-Q · filed 2025-11-13 | 715.32K shares 10-Q · filed 2025-11-13 | ||||||
| 2025-06-30 | 754.94K shares 10-Q · filed 2025-08-12 | 754.94K shares 10-Q · filed 2026-08-12 | ||||||
| 2025-03-31 | 769.61K shares 10-Q · filed 2026-05-14 | |||||||
| 2024-12-31 | 469.65K shares 10-K · filed 2026-03-27 | |||||||
| 2024-09-30 | 476.76K shares 10-Q · filed 2025-11-13 | 476.76K shares 10-Q · filed 2025-11-13 | ||||||
| 2024-06-30 | 490.55K shares 10-Q · filed 2025-08-12 | 490.55K shares 10-Q · filed 2025-08-12 | 2.45M shares 10-Q · filed 2024-08-09 | |||||
| 2024-03-31 | 497.13K shares 10-Q · filed 2025-05-13 | 2.49M shares 10-Q · filed 2024-05-09 | ||||||
| 2023-12-31 | 505.42K shares 10-K · filed 2025-03-31 | 2.53M shares 10-K · filed 2024-03-28 | ||||||
| 2023-09-30 | 2.58M shares 10-Q · filed 2023-11-09 | 516.17K shares 10-Q · filed 2024-11-08 | 2.58M shares 10-Q · filed 2023-11-09 | |||||
| 2023-06-30 | 2.64M shares 10-Q · filed 2023-08-10 | 2.64M shares 10-Q · filed 2024-08-09 | ||||||
| 2023-03-31 | 2.75M shares 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | 1.92M shares 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | 1.93M shares 10-Q · filed 2023-11-09 | 1.93M shares 10-Q · filed 2023-11-09 | ||||||
| 2022-06-30 | 2.22M shares 10-Q · filed 2023-08-10 | 2.22M shares 10-Q · filed 2023-08-10 | ||||||
| 2022-03-31 | 2.55M shares 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | 1.66M shares 10-K · filed 2023-03-23 | |||||||
| 2021-09-30 | 1.76M shares 10-Q · filed 2021-11-12 | |||||||
| 2021-06-30 | 1.67M shares 10-Q · filed 2022-08-11 | |||||||
| 2021-03-31 | 1.60M shares 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | 1.30M shares 10-K · filed 2022-03-24 | |||||||
| 2020-09-30 | 1.30M shares 10-Q · filed 2021-11-12 | |||||||
| 2020-06-30 | 1.34M shares 10-Q · filed 2021-08-12 | 1.30M shares 10-Q · filed 2020-08-06 | ||||||
| 2020-03-31 | 1.34M shares 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | 1.09M shares 10-K · filed 2021-03-25 | |||||||
| 2019-09-30 | 1.11M shares 10-Q · filed 2020-11-12 | |||||||
| 2019-06-30 | 1.11M shares 10-Q · filed 2020-08-06 | |||||||
| 2019-03-31 | 1.11M shares 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | 1.11M shares 10-K · filed 2020-03-27 | |||||||
| 2018-09-30 | 661.43K shares 10-Q · filed 2019-11-12 | 1.09M shares 10-Q · filed 2018-11-09 | ||||||
| 2018-06-30 | 661.43K shares 10-Q · filed 2019-08-08 | |||||||
| 2018-03-31 | 690.60K shares 10-Q · filed 2019-05-10 | |||||||
| 2017-12-31 | 658.59K shares 10-K · filed 2019-02-26 | |||||||
| 2017-09-30 | 618.59K shares 10-Q · filed 2018-11-09 | |||||||
| 2017-06-30 | 555.52K shares 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |